Immunotherapy before lung surgery shows promise in early trial

NCT ID NCT02259621

Ongoing Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Dec 18, 2025 · Last updated Jun 18, 2026 · Updated 31 times

Summary

This study tested giving the immunotherapy drugs nivolumab (with or without ipilimumab) before surgery to people with a type of lung cancer called non-small-cell lung cancer. The goal was to see if this approach is safe and helps shrink tumors before removal. 39 participants were enrolled, and researchers measured side effects and how much tumor remained after surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Johnathan Spicer

Montreal, Quebec, H4 3J1, Canada
Johns Hopkins at Bayview Medical Center

Baltimore, Maryland, 21224, United States
Memorial Sloan Kettering

New York, New York, 10065, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21287, United States
Swedish Cancer Insitute

Edmonds, Washington, 98026, United States

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER